Kyowa Kirin Co Ltd represents a set of core values and corporate philosophy. The company prioritizes the health and well-being of patients, aiming to contribute to the advancement of medical science and enhance the quality of life. Kyowa Kirin Co Ltd focuses on innovation, putting patient needs at the forefront of its research and development activities. The company believes in collaboration and partnerships to drive progress in delivering novel therapies and addressing unmet medical needs. With a commitment to integrity and ethical business practices, Kyowa Kirin Co Ltd strives to make a positive impact and improve the lives of patients worldwide.

Kyowa Kirin Co Ltd is primarily present in Japan, where it is headquartered. Additionally, the company has a significant presence in other countries and regions worldwide. These include the United States, where it operates through a subsidiary, as well as various regions in Europe, including the United Kingdom, Germany, France, and Switzerland. With a global reach and a strong presence in multiple markets, Kyowa Kirin Co Ltd is able to leverage its expertise and product offerings across different regions to optimize its business operations and serve a diverse customer base effectively.

Kyowa Kirin Co Ltd, a leading pharmaceutical company, has achieved noteworthy milestones over the years. Notably, the company successfully developed and launched several groundbreaking medicines, such as Poteligeo, a treatment for skin conditions like cutaneous T-cell lymphoma. Additionally, Kyowa Kirin Co Ltd secured regulatory approvals for novel therapies like CRYSVITA, a treatment for rare bone diseases. Furthermore, the company built strategic alliances and partnerships to expand its global footprint and enhance research capabilities. In recent years, Kyowa Kirin Co Ltd has shown a strong commitment to innovation and patient care, continuously striving to improve the lives of individuals worldwide through its breakthrough advancements.

Kyowa Kirin Co Ltd, formerly known as Kyowa Hakko Kirin Co Ltd, is a leading Japanese pharmaceutical company. Founded in 1949, it has a rich history and background in the healthcare sector. Kyowa Kirin specializes in the research, development, manufacturing, and marketing of innovative and life-saving pharmaceuticals. Over the years, the company has been dedicated to delivering high-quality medicines for a wide range of diseases, including cancer, renal diseases, and immune disorders. With a strong emphasis on scientific research and technological advancements, Kyowa Kirin has established itself as a trusted and reliable name in the global pharmaceutical industry.

The main competitors of Kyowa Kirin Co Ltd in the market include other pharmaceutical and biotechnology companies such as Takeda Pharmaceutical Company Limited, Eisai Co Ltd, and Astellas Pharma Inc. These companies also operate in the healthcare sector, developing and selling various drugs and therapies. Kyowa Kirin Co Ltd competes with these companies in terms of research and development, product pipelines, market share, and global presence.

Kyowa Kirin Co Ltd is primarily active in the pharmaceutical and biotechnology industries.

The business model of Kyowa Kirin Co Ltd is focused on the development, manufacturing, and commercialization of specialty pharmaceuticals. The company primarily operates in the fields of nephrology, oncology, and immunology. Kyowa Kirin Co Ltd strives to bring innovative and high-quality therapeutic solutions to patients worldwide. With a strong commitment to research and development, the company invests in advancements in biotechnology and strives to address unmet medical needs. Kyowa Kirin Co Ltd also collaborates with global partners to expand its product portfolio and reach a wider patient population, all while maintaining a strong focus on patient-centricity and improving healthcare outcomes.

P/E odnos Kyowa Kirin Co iznosi 24,67.

KUV kompanije Kyowa Kirin Co iznosi 3,45.

AlleAktien kvalitativni skor za Kyowa Kirin Co je 7/10.

očekivana Kyowa Kirin Co promet je 482,83 milijardi JPY.

Dobit očekivana Kyowa Kirin Co je 67,57 milijardi JPY.

Kyowa Kirin Co Ltd is a global pharmaceutical company based in Japan that focuses on the development, manufacturing, and marketing of medications for patients with rare diseases. The company's business operations are divided into four segments: 1. Pharmaceutical Business: Kyowa Kirin focuses on researching and developing innovative medications for patients with rare diseases or unmet medical needs. The portfolio includes treatments for diseases such as kidney diseases, cancer, blood disorders, immunological diseases, neurological diseases, and heart diseases. 2. Bio-Chemicals Business: Kyowa Kirin produces biochemical products for biotech companies and research institutions worldwide. The company is capable of manufacturing a wide range of biochemicals, enzymes, reagents, and active ingredients at the highest level. 3. Vaccines Business: Kyowa Kirin focuses on developing vaccines against life-threatening diseases in this segment. Kyowa Kirin's experts have decades of experience in vaccine development, significantly supporting the containment of infectious diseases. 4. Renal Diseases Business: The Renal Diseases Business segment provides innovative solutions for patients with kidney diseases. This target group includes particularly patients suffering from life-threatening chronic kidney diseases and in need of a kidney transplant. In this context, the product "Nesp" (Darbepoetin alfa) was developed to stimulate erythropoietin production, which promotes the formation of red blood cells. Kyowa Kirin Co Ltd is committed to improving lives and developing life-saving treatments for patients. The company employs a highly diversified business strategy. The aim is to increase the profitability of each business segment by combining the company's strengths in areas such as drug development, analysis and synthesis technology, clinical trials, production, and distribution. As a leading pharmaceutical company, Kyowa Kirin Co Ltd strives to continuously provide high-quality services to patients. To achieve this, the company collaborates closely with partners from the scientific and industrial sectors, as well as patient organizations worldwide. Kyowa Kirin also aims to act responsibly and integrate sustainable practices into all aspects of its business.

Kyowa Kirin Co isplaćuje dividendu od 51,00 JPY raspoređenu preko isplata u toku godine.

Dividenda za Kyowa Kirin Co trenutno ne može biti izračunata ili kompanija ne isplaćuje dividendu.

ISIN od Kyowa Kirin Co je JP3256000005.

WKN od Kyowa Kirin Co je 858523.

Oznaka za praćenje akcija kompanije Kyowa Kirin Co je 4151.T.

U poslednjih 12 meseci, Kyowa Kirin Co je isplatio dividendu u iznosu od 56,00 JPY . To odgovara dividendnom prinosu od oko 1,81 %. Za narednih 12 meseci, Kyowa Kirin Co će verovatno isplatiti dividendu od 57,97 JPY.

Dividendski prinos od Kyowa Kirin Co trenutno iznosi 1,81 %.

Kyowa Kirin Co isplaćuje dividende na kvartalnom nivou. One se isplaćuju u mesecima јул, јануар, јул, јануар.

Kyowa Kirin Co je isplaćivao dividendu svake godine u poslednjih 23 godina.

Za narednih 12 meseci očekuju se dividende u iznosu od 57,97 JPY. To odgovara dividendnom prinosu od 1,87 %.

Kyowa Kirin Co se svrstava u sektor 'Zdravlje'.

Da biste primili poslednju dividendu od Kyowa Kirin Co od 1. 3. 2025. u iznosu od 29 JPY, morali ste da imate akciju u depou pre Ex-dana 27. 12. 2024..

Isplata poslednje dividende izvršena je 1. 3. 2025..

U godini 2023 kompanija Kyowa Kirin Co je isplatila 51 JPY kao dividende.

Dividende od Kyowa Kirin Co se isplaćuju u JPY.